1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct gluca…
This comprehensive review underscores the immense potential of novel drug targets, innovative drug classes, and cutting-edge technologies to revolutionize the treatment landscape for metabolic diseases. The insights g…
These findings establish hypothalamic Cav3.1 as a crucial neuronal leucine sensor, providing a novel and fundamental understanding of how dietary protein influences satiety and body weight. This discovery suggests tha…
This review provides crucial reassurance for both clinicians and patients regarding the thyroid safety profile of GLP-1 RAs, particularly concerning the previously raised concerns about medullary thyroid carcinoma (MT…
The development of multi-agonist incretin therapies and novel non-incretin pathways represents a critical advancement, offering more potent and comprehensive treatment options for obesity and Type 2 Diabetes than ever…
This study identifies a novel mechanism by which Oroxylin A can combat NAFLD, highlighting its potential as a therapeutic agent. By modulating CPT1A through m6A methylation, Oroxylin A directly addresses the core meta…
This Phase 1 study is critically important as it seeks to understand the fundamental metabolic mechanisms of survodutide, a novel therapeutic candidate for obesity. If survodutide demonstrates superior or distinct ben…
Establishing bioequivalence between different delivery devices for Survodutide is a critical step for its future clinical development and patient accessibility. If the pre-filled syringe and pen deliver the drug equiv…
If successful, this Phase 2 trial could represent a significant advancement in the treatment of chronic kidney disease, a condition with high morbidity and mortality. A drug that can effectively reduce albuminuria cou…
This study highlights Dapagliflozin's potential as a valuable adjunctive therapy for Type 1 Diabetes patients struggling with optimal glycemic control despite existing Insulin and Liraglutide regimens. The observed be…
This large-scale Phase 3 trial is crucial for understanding the long-term cardiovascular impact of survodutide, a novel anti-obesity agent. A positive outcome would establish survodutide as a safe and effective treatm…
The successful outcome of this Phase III trial could represent a monumental step forward in treating MASH, a condition affecting millions globally with no current pharmacological cure. If Survodutide demonstrates sign…
As this is an active, not-yet-recruiting Phase 1 study (NCT07221591), specific results regarding the relative bioavailability of the two survodutide formulations are not yet available. The primary objective is to asse…
This pilot study represents a novel approach to Type 2 Diabetes Mellitus management, focusing on an intensive, short-term intervention to potentially reverse or significantly improve disease progression. If successful…
These hypothetical findings suggest that GLP-1 receptor agonists like Liraglutide or GIK infusions could offer safer and more effective perioperative glycemic control for patients with Type II Diabetes Mellitus underg…
Understanding the real-world effectiveness of combination therapies like Xultophy® is crucial for optimizing Type 2 Diabetes management. This study provides valuable data on how a fixed-ratio combination of insulin de…
This study provides compelling evidence that combining cagrilintide and semaglutide offers a highly effective and synergistic therapeutic strategy for achieving substantial and clinically meaningful weight loss, surpa…
The Cagrilintide-Semaglutide combination group demonstrated a remarkable mean body weight reduction of 22.6% from baseline over the 68-week study period, which was statistically significantly superior to all other gro…
This study provides compelling evidence that CagriSema not only facilitates significant weight loss but also directly and substantially improves blood pressure in individuals with overweight or obesity and hypertensio…
This guidance is crucial for plastic surgeons, as it provides a framework to identify and manage nutritional deficiencies that can directly impact the safety and success of body contouring procedures. By understanding…
This study provides valuable real-world evidence regarding the effectiveness and utilization of liraglutide for weight management outside of controlled clinical trial settings. The findings can help inform healthcare …
Developing long-acting GLP-1 receptor agonists is paramount for improving patient adherence and convenience in the long-term management of Type 2 Diabetes. If LAPS-Exendin (HM11260C) demonstrates favorable safety and …
This study is significant because it investigates strategies to improve the long-term management of Type 2 Diabetes, moving beyond conventional insulin regimens. The expected findings suggest that combining insulin wi…
This Phase 3 trial represents a critical step towards providing new, effective treatment options for children and adolescents struggling with overweight and obesity. If successful, the study could establish Cagrilinti…
Understanding the pharmacokinetic equivalence and performance of different CagriSema formulations and delivery devices is crucial for its continued development as a combination therapy for obesity. This study's findin…
This meta-analysis provides compelling evidence that CagriSema, combining a GLP-1 receptor agonist (semaglutide) with an amylin analog (cagrilintide), offers a substantially more potent and effective treatment option …
While specific pharmacokinetic data (e.g., Cmax, AUC values) are not detailed in this record, the study successfully completed its Phase 1 objectives, enrolling 40 participants and evaluating the drug exposures over a…
This comprehensive review underscores amylin's critical, yet often underutilized, potential as a therapeutic agent for diabesity. Its unique mechanisms, including appetite suppression and improved glucose regulation, …
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
Cagrisema represents a highly potent and promising new therapeutic option for individuals struggling with obesity, offering superior weight loss efficacy and improved metabolic parameters compared to current gold-stan…
This comprehensive review underscores Semaglutide's position as a highly effective pharmacological intervention for obesity, offering substantial and sustained weight loss that can significantly improve health outcome…
This study provides compelling evidence that GLP-1 Receptor Agonists offer significant protective benefits beyond glycemic control, extending to both systemic and ocular vascular health in a high-risk population. Thes…
Mazdutide's dual GLP-1R and GCGR agonism offers a unique mechanism that appears to drive superior weight loss and broader metabolic improvements compared to single-target therapies. This comprehensive metabolic benefi…
This study highlights Survodutide's potential as a groundbreaking treatment for obesity and MASH, leveraging a dual mechanism of action through GLP-1 and glucagon receptor agonism. Its ability to induce substantial we…
This research solidifies Liraglutide's role as a cornerstone therapy for managing Type 2 Diabetes and Obesity, offering not only robust glycemic control and significant weight reduction but also crucial cardiovascular…
This study is crucial because it focuses on affordable and accessible interventions for a population disproportionately affected by metabolic and cardiovascular diseases. Identifying effective, well-tolerated, and cos…
This Phase 1 study is a crucial step in the development of a potentially improved oral semaglutide formulation. Understanding the pharmacokinetics of oral semaglutide D under various dosing conditions is essential for…
This study is crucial for understanding the mechanisms by which semaglutide promotes weight loss and improves metabolic health, particularly at the 2.4 mg dose. The anticipated significant slowing of gastric emptying …
This large-scale data analysis is crucial for understanding the potential neuroprotective effects of different diabetes medications. If Semaglutide demonstrates a significantly lower risk of dementia/Alzheimer's disea…
The successful outcome of this trial could represent a paradigm shift in managing the complex interplay of Type 1 Diabetes and obesity. If Tirzepatide proves safe and effective, it could offer a novel therapeutic opti…